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ABSTRACT: Direct interactions between proteins are essential for the
regulation of their functions in biological pathways. Targeting the complex
network of protein−protein interactions (PPIs) has now been widely
recognized as an attractive means to therapeutically intervene in disease
states. Even though this is a challenging endeavor and PPIs have long been
regarded as “undruggable” targets, the last two decades have seen an
increasing number of successful examples of PPI modulators, resulting in
growing interest in this ﬁeld. PPI modulation requires novel approaches and
the integrated eﬀorts of multiple disciplines to be a fruitful strategy. This
perspective focuses on the hub-protein 14-3-3, which has several hundred
identiﬁed protein interaction partners, and is therefore involved in a wide
range of cellular processes and diseases. Here, we aim to provide an
integrated overview of the approaches explored for the modulation of 14-3-3
PPIs and review the examples resulting from these eﬀorts in both inhibiting
and stabilizing speciﬁc 14-3-3 protein complexes by small molecules, peptide mimetics, and natural products.
■ INTRODUCTION
Protein−Protein Interactions (PPIs). Protein−protein
interactions (PPIs) are important in almost all biological
processes. Most proteins do not function as single isolated
entities but rather are engaged in a dynamic physical network
with other proteins in the biomolecular context of a cell and its
environment, often as part of a multiprotein complex. This
makes the interactions of proteins as important as the
biochemical activity of the protein itself. To understand the
biological role of a protein, it is of great importance to understand
andmanipulate its underlying PPI network. An excellent example
of this can be found in cancer biology, where the oncogenic
kinase B-Raf can activate or inhibit the MAPK pathway by
mechanisms that involve changes in the interactions of B-Raf
with other members of the Raf kinase family.1−3
The “druggable genome” has been initially estimated to
comprise approximately 1,500 single protein targets.4 Although
this is still many more than the 266 human protein targets
addressed by currently approved drugs,5 intentionally targeting
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PPIs signiﬁcantly enlarges this number. The targeting of PPIs will
be particularly valuable for diseases that cannot be addressed via
“conventional” targets such as enzymes, receptors, or ion
channels. By considering PPIs occurring in the human body,
this situation can undoubtedly be improved given the size of the
so-called protein−protein “interactome” with estimates lying
between 130,0006 and 650,0007 protein complexes. Successfully
addressing PPIs will vastly expand our opportunities for
pharmacological intervention, especially by exploiting natural
products.8 However, our understanding of biological mecha-
nisms, and thus also which PPIs are relevant to disease, is still
rudimentary. No further evidence of this is needed other than to
reﬂect on the fact that the highest attrition rate during the drug-
discovery process occurs during phase II clinical trials when it
also becomes more costly.9 This attrition all too often arises
because the desired biological eﬀect is not observed with a given
lead candidate. The availability of a good chemical probe, in
contrast to genetic methods, uniquely allows temporary and
titratable knockdown of a protein of interest, permitting its
“druggability” and relevance to disease to be evaluated.10−12 Such
probes can drive fundamental biology; for instance, publications
on BRD4 (bromodomain) and hDM2 (ubiquitin ligase) have
increased dramatically since the discovery of the PPI inhibitors
bromodomain inhibitor (JQ1)13 and Nutlin.14
The issue of “druggability” is not unique to PPIs. However,
their extensive regulatory role in biological mechanisms dictates
that high-quality tool compounds modulating PPIs are urgently
required as probes of healthy/disease biology and to provide
starting points for drug discovery. Here, PPIs present a further
challenge in that the interacting surfaces are larger, ﬂatter, and
generally deﬁcient in the “binding-pockets” that deﬁne conven-
tional ligandable15,16 proteins,9 although identiﬁcation of hot-
spots17 permits a binding site to be deﬁned. This challenge is
suﬃciently daunting that, until recently, PPIs were considered
too challenging tomodulate using small-molecules and amenable
only tomodulation using biologics.18 However, the emergence of
PPIs as small-molecule targets has now been conclusively
demonstrated by the Nutlin series (Roche)14 and Navitoclax
(Abbott).22 Although traditional approaches (e.g., high-
throughput screening, fragment-based drug discovery, and
computer-aided ligand design) are recognized as having
limitations in terms of the identiﬁcation of hit matter,19,20 the
development of design-based approaches, e.g., based on
foldamers, is encouraging.21 A number of strategic approaches
to modulation can be envisioned comprising competitive (or
orthosteric) inhibition, allosteric inhibition, and stabilization
(Figure 1A−C) with general progress in this area summarized in
numerous well-cited reviews.16,19,20,23−27 In terms of interven-
tion within a pathway, the biological eﬀect might be complex in
that competitive inhibition of a PPI might result in stabilization
of a PPI elsewhere within the pathway. Similarly, allostery aﬀects
not only the activation state of a given protein but the entire
pathway in which it is embedded.28 For instance, the GTPase
activity of Ras is modulated through its PPI with SOS at a remote
site, and modulation of this interaction aﬀects downstream PPI-
mediated kinase activity within the entire pathway.29
In terms of ligand approaches, competitive, allosteric, and
stabilization modulation of PPIs are extremely diﬀerent.
Competitive inhibition is reasonably well established, and a
number of inhibitors have been identiﬁed using conventional
drug-discovery and design approaches. Prominent examples
include a Nutlin follow-up from Roche (RG7112),30 Abbott
(ABT-199),31 and GSK (I-BET762),32 which all entered clinical
trials (Figure 2A−C). Challenges associated with competitive
inhibition center on achieving suﬃciently potent and selective
recognition of either protein surface for inhibition to occur and
the concomitant liability that might be introduced in terms of
inhibiting all PPIs of the target protein. The biological response is
proportional to the quality of the competitor. Allosteric
inhibition may be more challenging to achieve by “design” and
more likely to be identiﬁed by chance; however, allosteric
inhibitors oﬀer increased selectivity and self-limiting activity and,
where PPIs are concerned, are much more likely to have the
Lipinski properties33 characteristic of traditional small molecule
drugs. A number of natural products have been identiﬁed to act
through allosteric eﬀects such as Taxol, which stabilizes tubulin
so as to retard its polymerization.34 Drug-discovery and chemical
biology programs have also delivered allosteric modulators. For
instance, allosteric inhibitors of HIF-2 complex formation have
been identiﬁed, which act through recognition of the PAS-B
domain of the HIF-2α subunit (Figure 2D).35 Such compounds
have been used to validate HIF-2 as a viable cancer target in renal
cell cancer.36,37 Stabilization is less well established; however, it
features prominently among natural products Brefeldin A,38
Forskolin,39 and Rapamycin40 (among others), which all act
through stabilization of a PPI (Figure 2E and F). In addition,
Tafamidis, one of the few PPI modulators to successfully reach
the clinic, stabilizes the PPI transthyretin, which normally exists
as a functional tetramer and aggregates in neurodegenerative
diseases such as transthyretin amyloidosis. Small molecules such
as Tafamidis that recognize and stabilize the tetrameric complex
have been shown to kinetically retard aggregation and thus
amyloid ﬁbril formation.41,42 It should be noted that stabilizers of
PPIs should also exhibit self-limiting biological response and
greater selectivity because they also rely on ternary complex
formation.
Despite these advances, PPI modulation remains a largely
unsolved problem with inhibitors against only a few targets in
current clinical trials.20 Progress is hampered by low success rates
in identifying high-quality starting points for drug discovery19
and by a poor understanding of which PPIs may be targeted by
small molecules.16 Improved ligand-discovery approaches and
better conceptual understanding might well arise from the study
of certain privileged protein classes. With several hundred
identiﬁed protein interaction partners in eukaryotic cells, the
family of the so-called 14-3-3 proteins is an especially interesting
case for small-molecule PPI modulation. This protein family
represents an outstanding testing ground for new conceptual
approaches to PPI modulation and the elaboration of novel
Figure 1. Schematic depicting diﬀerent strategies for modulation of
PPIs: competitive (orthosteric) inhibition (A), allosteric inhibition (B),
and stabilization (C).
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therapeutic approaches. PPIs of 14-3-3 proteins play key roles in
numerous disease-relevant biological pathways and oﬀer clear
opportunities in terms of inhibition and stabilization. This
perspective will highlight the state of the art in both areas with
examples from diverse disease pathways.
14-3-3 Proteins. 14-3-3 proteins are eukaryotic adaptor
proteins involved in many cellular processes such as cell-cycle
control, signal transduction, protein traﬃcking, and apoptosis.44
By binding to other proteins, 14-3-3 can assist in protein folding,
protein localization, and stimulation or inhibition of other
PPIs.45 Seven diﬀerent mammalian 14-3-3 isoforms exist (α/β, γ,
σ, δ/ζ, η, ε, and τ), which are highly conserved throughout
species and mainly exist as dimers. Each monomer consists of
nine alpha helices forming an amphipathic groove that can bind
to (mostly phosphorylated) protein partners (Figure 3).46
Among the several hundred 14-3-3 interaction partners
described so far, there are many disease-relevant proteins
involved in key cellular processes, like the Raf kinases,47,48 cell-
cycle phosphatase Cdc,49,50 transcriptional modulator YAP51,52
and tumor suppressor p53.53,54 This widespread involvement in
human disease makes 14-3-3 proteins a highly interesting case for
the development of technology to modulate their PPIs in a
speciﬁc and eﬃcient manner. Because both inhibition and
stabilization of 14-3-3 PPIs have been shown with small
molecules, the possibilities for novel pharmacological inter-
vention by addressing this protein class are substantial. In this
context, stabilization of 14-3-3 PPIs is an especially promising
approach because the problem of speciﬁcity might be solved
more easily than with inhibitors. This is due to the relatively high
variability between the respective PPI interfaces. This variability
might allow for the development of compounds that speciﬁcally
bind to unique composite pockets at the PPI interfaces. In this
Figure 2.Representative examples of competitive, allosteric, and stabilizing PPI ligands (X-ray structure (above), chemical structure (below)). (A) p53/
hDM2 inhibitor RG7112 (PDB ID: 4IPF).43 (B) BH3/Bcl-2 inhibitor ABT-199 (PDB ID: 4MAN).31 (C) Fragment of BRD4/Histone inhibitor I-
BET762 (PDB ID: 4C66).32 (D) HIF-2 PAS domain allosteric modulator (PDB ID: 4GHI).35 (E) FKBP12/Rapamycin/FRAP stabilizer complex
(PDB ID: 1FAP).40 (F) Transthyretin stabilizer (PDB ID: 2FLM).42
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way, not only can tool compounds be developed for the study of
the underlying biology in, e.g., cancer, neurodegeneration,
metabolic diseases, infection, and cystic ﬁbrosis, but the approach
can also be exploited in terms of drug discovery. Here, control of
subcellular localization, enzymatic activity, and biological half-life
can be envisioned as modes by which 14-3-3 PPI modulators
could act, e.g., on transcription factors (YAP, c-Jun, MLF1,
FOXOs), enzymes shuttling between cytoplasm and nucleus
(Cdc25 phosphatases, HDACs), or kinases (B, C-Raf, LRRK2).
In recent years, a growing number of crystal structures of 14-3-
3 in complex with diﬀerent binding partner motifs have been
published, for example, the cystic ﬁbrosis ion channel CFTR,55
the small heat shock protein HSPB6,56 phosducin,57 and the
Parkinson’s disease-related kinase LRRK2.58 As dimeric species
that dock onto pairs of speciﬁc phosphorylated serine- or
threonine-containing motifs, 14-3-3 proteins are endowed with
special signaling, mechanical, and evolutionary properties.
Although there are a few cases where a 14-3-3 dimer interacts
simultaneously with phosphorylated sites in two diﬀerent targets,
in most documented cases a single 14-3-3 dimer binds to two
phosphorylated sites that lie in tandem in the same target protein.
This means that a 14-3-3 dimer can act as a signaling integrator
when two binding sites on a target are phosphorylated by
diﬀerent kinases. The mechanical eﬀect of 14-3-3 will depend on
the location of the two docking sites. For example, these paired
sites may straddle a domain or motif whose function is masked by
the 14-3-3, or 14-3-3 binding to a disordered region can force a
disorder-to-order transition that creates a new functional site in
the target.59,60
14-3-3 binding sites lie within motifs that are phosphorylated
by basophilic protein kinases such as PKB/Akt, p90RSK, PKA,
and AMPK.57 This means that 14-3-3 aﬃnity capture and
quantitative mass spectrometry procedures can be used to
identify targets of, for example, regulation by insulin, growth
factors, energy stress, and adrenalin that activate these respective
kinases. In this way, new 14-3-3-based mechanisms have been
identiﬁed to explain how insulin and growth factors regulate
synchronized shifts in glucose uptake, glycolysis, mTORC1
signaling, protein translation, and other regulatory events that
promote cell growth and proliferation.62−64 Their roles as
mediators of growth factor and nutrient signaling pathways are
consistent with further ﬁndings that connect 14-3-3 proteins to a
variety of human diseases. In addition to their participation in
diverse cancers,44 they have been associated with the develop-
ment of neurodegenerative diseases65 and virulence of human
pathogenic organisms.66,67
The role of 14-3-3 proteins in parasitic organisms has only
recently emerged. The rising interest in this ﬁeld is justiﬁed by
the limited panel of eﬀective drugs currently available to treat
parasite infections, the relevant side eﬀects associated with these
compounds, and the growing number of treatment-refractory
cases.68 A survey of the recent literature has highlighted a number
of reports showing the role of, and in a few cases the structural
features of, 14-3-3 from parasites, which are brieﬂy reviewed here.
Plasmodium falciparum and Plasmodium knowlesi are two
species of protozoan parasites that can cause severe malaria
infection in humans.69 In P. falciparum and P. knowlesi, the single
isoform of 14-3-3 was shown to act as a chaperone only in speciﬁc
life stages of the parasite.68 In Plasmodium berghei, the host
skeletal protein dematin is translocated from the erythrocyte
membrane within the parasite, where it interacts with the
Plasmodium 14-3-3, thus inﬂuencing the remodeling of the
Figure 3. 14-3-3 structure and binding of partner protein peptides exempliﬁed by the 14-3-3ζ/C-Raf complex (PDB ID: 4FJ3).61 Top: the physiological
14-3-3 dimer can accommodate two phosphorylated peptide motifs. In the case of C-Raf, two of these motifs (pSer233 and pSer259) are located in the
N-terminal region of this protein kinase. When synthesized as a diphospho peptide (C-RafpS233pS259) and crystallized with 14-3-3ζ dimer, a
signiﬁcant proportion of the peptide does not engage an intimate contact with 14-3-3 and is thus not visible in the X-ray crystal structure (right dimer:
green dotted line). Bottom: C-RafpS259 site accommodated in the groove of a 14-3-3ζ monomer.
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erythrocytic cytoskeleton and modulating the host erythrocyte
invasion.70
Eimeria tenella is a coccidian parasite that causes a serious
intestinal disease in chickens. Although human infection by E.
tenella has not been reported yet, this parasite has a signiﬁcant
economic impact with an estimated cost to the poultry industry
of around $2.4 billion per annum worldwide, thus justifying the
in depth study of its lifecycle and infection mechanisms.71 In E.
tenella, a single isoform of 14-3-3 seems to be involved in the
regulation of the mannitol pathway. In particular, the binding of
14-3-3 to the mannitol-1-phosphate dehydrogenase (M1PDH)
was shown to inactivate the enzyme as soon as mannitol
biosynthesis is complete. From a drug discovery perspective, it is
important to note that this pathway is missing in higher
eukaryotes, thus representing an attractive target for the
development of selective drugs.68
Toxoplasma gondii is a protozoan parasite that causes a disease
known as toxoplasmosis, a generally asymptomatic infection.
Despite this, the parasite is known to cause severe congenital
infection in humans and animals. The sexual reproduction of this
parasite occurs in the intestine of deﬁnitive hosts (cats) while
asexual multiplication takes place in various hosts, including
humans.72 14-3-3 proteins have been detected in the asexual
form of the parasite, namely the tachyzoite stage, that is virulent
in humans.73 Moreover, it was demonstrated that, in this stage,
14-3-3 proteins from T. gondii induce hypermotility in infected
host cells.74
Alveolar echinococcosis (AE) is a rare parasitic disorder that
occurs after ingestion of eggs of Echinococcus multilocularis. AE is
a tumorlike chronic disease, which can be fatal if left untreated.75
In E. multilocularis, 14-3-3 proteins have been reported to be
implicated in the tumor-like growth process.76 Furthermore, it
has been hypothesized that overexpressed 14-3-3 proteins may
be involved in the promotion and/or maintenance of the
progressive growth capacity of E. multilocularis larvae.77
Schistosoma mansoni is one of the major intestinal parasites that
can cause schistosomiasis, the most widespread parasitic disease
after malaria. This parasite encodes four 14-3-3 isoforms that
have roles in host immunity, parasite development, and
survival.78
Trichinella spiralis is a nematode parasite that is responsible for
the development of trichinellosis, which is an important
foodborne parasitic disease worldwide. The infection in humans
is generally acquired by eating raw or inadequately cooked meat
that contains encysted larvae of T. spiralis. 14-3-3 proteins from
this parasite were shown to play a crucial role in the early stages of
the infection by maintaining the host−parasite relationship.79
Cryptosporidium parvum is a parasite responsible for
cryptosporidiosis, a diarrheal disease that aﬀect humans and
animals especially in developing countries.80 This infection is
mainly caused by the ingestion of contaminated water, and an
estimated 748,000 cryptosporidiosis cases occur annually.81
Unfortunately, only a limited number of drugs can be used to
treat infections by C. parvum and most of them have low eﬃcacy
and an unknown mechanism of action. The three isoforms of 14-
3-3 found in C. parvum (Cp14ε, Cp14a, and Cp14b) were
crystallized in 2011, and two of them showed some interesting
features that are unique among 14-3-3 proteins.80 In particular, in
the isoform Cp14a, the substrate pocket is much more open
compared to the classical folding of 14-3-3, leading to the
hypothesis that this isoform can accommodate large substrates.
The Cp14b isoform was able to bind a phosphorylated copy of
the last six amino acid residues of its own C-terminus. This
binding is much stronger when the C-terminus is truncated, thus
suggesting a competition between C-terminus and its
phosphorylated mimic.80 Even if other studies are necessary to
understand the role of 14-3-3 in the C. parvum life cycle, these
unique features described above can be exploited to develop
novel strategies for cryptosporidiosis treatment.
Giardia duodenalis is a protozoan parasite that causes giardiasis
by colonizing the upper portion of the small intestine in
mammals. Giardiasis is the most common gastrointestinal
diarrheal illness worldwide, and more than 200 million
symptomatic human cases are reported annually.82,83 In this
parasite, the single 14-3-3 isoform (g14-3-3) is essential for the
development of cysts (the infective stage).84
Three crystallographic structures ofG. duodenalis are available,
which makes this protein amenable to study through structure-
based computational methods. The crystal structure of g14-3-3 in
the apo form revealed an unusual “open” conformation,85
whereas computational studies (supported by crystallographic
evidence) proved that the post-translational modiﬁcation
(phosphorylation) on Thr214 of g14-3-3 induces a conforma-
tional rearrangement that leads to the “closed” and stable g14-3-3
conformation.84 This form corresponds to the peptide-bound
g14-3-3 structure.
In summary, all these ﬁndings demonstrate that 14-3-3
proteins have substantial involvement in parasites’ life cycles.
Even if the molecular basis for the role of 14-3-3 in pathogenicity
is not well understood, we can speculate that this protein family
could represent an alternative and promising axis to treat parasite
infections. Despite rising interest in the role of 14-3-3 in
parasites, signiﬁcant advancement in basic research is required.
Speciﬁcally, the development of a 14-3-3 modulator could be
essential for unravelling the contribution of 14-3-3 proteins to
parasite growth and survival in the host.
In general, the ubiquity of 14-3-3 protein involvement in
numerous human diseases has sparked interest in their use as
novel targets for drug discovery.44,49,65,86 The fact that 14-3-3
proteins serve purely as adapter proteins means that active
compounds against 14-3-3 alone will impact several binding
partners and thus likely give rise to unwanted pharmacology.
However, if the drugs target the complex formation between 14-
3-3 and a protein partner, either by inhibition or stabilization,
then intrinsic speciﬁcity should be possible.24
Structural Biology of 14-3-3 PPIs.Most PDB entries of 14-
3-3 crystal structures represent binary complexes of 14-3-3 with a
peptide mimic of the phosphorylated binding site of the PPI
partner protein. Only in a limited number of cases has
crystallization of 14-3-3 with a larger part of the partner protein
been possible. One reason for the diﬃculty in obtaining full-
length structures of these complexes is the fact that the partner
proteins themselves are often multidomain proteins and thus
challenging to crystallize. A second reason is that the 14-3-3
binding sequences are prevalently localized in disordered regions
of their target proteins and only undergo a disorder-to-order
transition when binding to 14-3-3. In this transition, it is
common for only the directly neighboring parts of the
phosphorylated anchor residues to be involved. Thus, large
parts of the partner protein regions remain disordered, which is a
disadvantage for crystal growth. A commonly adopted alternative
strategy therefore centers on using synthetic peptides comprising
around 10−40 amino acid residues to mimic the partner protein
binding motif. It is of course vital that the activity of any stabilizer
or inhibitor found using the simpliﬁed 14-3-3/partner-protein-
peptide system is also shown in the context of more
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physiologically relevant partner protein constructs. So far,
however, crystallography of 14-3-3 in complex with synthetic
peptides has been a useful system to obtain structural data of 14-
3-3 modulators. These synthetic peptides typically bind in the
14-3-3 amphipathic binding groove like the 14-3-3ζ/C-Raf
complex shown in Figure 3. Additionally, many structures have
been reported where a small molecule is also bound to form a
ternary complex. Historically, 14-3-3 binding sequences have
been categorized in diﬀerent motifs. Mode I and II interaction
partners were deﬁned to require an arginine at position −3 with
respect to the phosphorylated serine or threonine residue and a
proline residue at position +2 (more speciﬁcally; (I) RSX(pS/
T)XP or (II) RX(F/Y)X(pS)XP).46 Mode III motifs were later
deﬁned as C-terminal sequences, where the phosphorylated
serine or threonine is the penultimate residue of the binding
partner.87 However, as recent reviews of the known 14-3-3
interactome have illustrated, 14-3-3 binding motifs can deviate
from these well-deﬁned motifs.60,88 Here, we will focus on
examples where a larger domain of the partner protein is
crystallized with 14-3-3: AANAT, PMA2, Hd3a (Figure 4), and
more recently for HSPB6 (Figure 5).56,89,90 This set of crystal
structures conveniently shows the variety of binding modes
possible with 14-3-3 and illustrates their relevance in the
identiﬁcation of important and distinct interaction interfaces.
14-3-3ζ/AANAT. Serotonin N-acetyltransferase (arylalkyl-
amine N-acetyltransferase, AANAT) catalyzes the transfer of
acetyl from acetyl-coenzyme A to serotonin, thus producing N-
acetylserotonin, which is the precursor of melatonin. Melatonin
levels are believed to govern the vertebrate daily rhythm with
high levels occurring at night thus providing a hormonal analog
signal of environmental lighting, which can be used to optimize
circadian physiology and possibly form the basis of treatment in
sleeping disorders.91,92 In 2001, the crystal structure of 14-3-3ζ in
complex with AANAT was published by the group of Dyda
showing that binding to 14-3-3 activates the enzyme by
signiﬁcantly increasing its aﬃnity for its substrates serotonin
Figure 4. Crystal structures of 14-3-3 complexes with larger partner protein constructs. (A) 14-3-3ζ/AANAT (PDB ID: 1IB1),89 (B) T14-3c/PMA2-
CT52 (PDB ID: 2O98),108 and (C) GF14c/Hd3a (PDB ID: 3AXY).107 Upper row: surface representation of the complex. Lower row: details of the
protein−protein complex interfaces.
Figure 5. Complex between 14 and 3-3σ and HSPB6. Both proteins bind in a 2:2 stoichiometry but in contrast to the examples displayed in Figure 4
interact in an asymmetric fashion with the ACD dimer of HSPB6 binding to one 14-3-3 monomer and both N-terminal domains in the phospho-
accepting grooves of 14-3-3 (PDB ID: 5LTW).56
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and acetyl-coenzyme A.89 In the crystal structure, two AANAT
monomers (residues 18−196) bind to the central channel of a
14-3-3 dimer (Figure 4A). In addition to the phosphorylation-
dependent interaction of the N-terminus of AANAT, which is
accommodated in an extended conformation by the amphipathic
groove of the 14-3-3 monomer, the well-structured C-terminal
part of the enzyme makes extensive contacts with the inner wall
of the 14-3-3 channel.
T14-3c/PMA2-CT52 Complex. The plant plasma mem-
brane H+-ATPase (PMA) generates both a chemical proton as
well as an electrical gradient (membrane potential) across the
plasma membrane.93 Because almost all transport mechanisms at
the plant plasma membrane are energetically dependent on the
PMA-generated electrochemical proton gradient, PMA plays a
central role in plant physiology as the powerhouse for plant
growth.94−97 One of the most important regulatory events for
PMA is phosphorylation of the penultimate C-terminal
threonine residue followed by binding of 14-3-3 proteins,
which activates PMA.98,99 This activation is strongly increased by
the natural product fusicoccin,100,101 which ﬁlls a gap in the
interface of 14-3-3 with the regulatory C-terminus (CT) of
PMA.102,103 The structure of the last 52 amino acid residues of
the C-terminus of the PMA isoform 2 (PMA2-CT52) from
tobacco (Nicotiana plumbaginifolia) in complex with Tobacco
14-3-3 isoform c (T14-3c) showed two PMAC-termini bound to
one 14-3-3 dimer (Figure 4B). The C-terminal 30 amino acid
residues bind as an elongated peptide and a short helix in the
amphipathic groove of each 14-3-3 monomer, whereas the N-
terminal 22 amino acid residues of PMA2-CT52 form a helix that
perpendicularly leaves the 14-3-3 binding channel.
14-3-3/Hd3a Complex. Approximately 80 years ago, a
substance was proposed to be synthesized in the leaves of
ﬂowering plants and transported to the shoot to induce
ﬂowering.104 This substance was named “ﬂorigen”, but its
molecular identity was uncovered by showing that “ﬂorigen” is
encoded by the highly conserved plant gene FLOWERING
LOCUS T (FT),105 whose product is a mobile protein.106 In
2011, it was shown that the FT protein from rice (Hd3a) binds to
14-3-3 proteins in the apical cells of shoots to form a complex
that migrates into the nucleus where it interacts with the basic
leucine zipper (bZIP) transcription factor FD.107 Interestingly,
the authors cocrystallized the complex between FT (Hd3a) and a
rice 14-3-3 protein (GF14c) and used crystals of the binary
complex to soak a short phosphopeptide derived from FD
(OsFD1) and obtain the ternary complex of GF14c/Hd3a/
OsFD1. In the crystal structure, the entire construct of Hd3a
(residues 6−170) is visible, making it the second-largest 14-3-3
partner protein after AANAT (residues 18−196) that has been
cocrystallized with 14-3-3. Two Hd3a molecules bind to one 14-
3-3 dimer and occupy an unusual position that is not part of the
central binding channel as seen with all other 14-3-3 ligands
including AANAT. Rather, Hd3a binds to the “upper” edges of
the horseshoe-like 14-3-3 dimer (Figure 4C). This site is close to
the additional Cdc25C binding site predicted by a mutation
study of human 14-3-3σ that lies outside of the central
phosphopeptide binding channel.90
14-3-3σ/HSPB6 Complex. In early 2017, Sluchanko,
Strelkov, and co-workers reported a 14-3-3 assembly with the
full-length HSPB6 dimer (Figure 5).56 The authors emphasize
this is the ﬁrst crystal structure of a human small heat shock
protein (HSP) in its functional state. The small HSPs comprise a
family of ten ATP-independent chaperones with molecular
masses in the range of 17−23 kDa.109 HSPB6 (also known as
HSP20) is involved in smooth muscle relaxation and cardio
protection and was identiﬁed as a binding partner for 14-3-3
upon phosphorylation of Ser16.109,110 HSPB6 dimerizes via its
highly conserved α-Crystallin domain (ACD) that forms a β-
sandwich, whereas both the N-terminal domain and C-terminal
extension (NTD and CTE) that ﬂank this region are highly
unstructured. The interaction motif for 14-3-3 consists of a
classical RRApSAP pattern located in the NTD.56
The authors cocrystallized 14-3-3 with two HSPB6-derived
phosphopeptides (residues 13−20 and 11−23) containing the
phosphorylated Ser16 before solving the structure of the full-
length pHSPB6 complex (residues 1−149) with 14-3-3σ to a
resolution of 4.5 Å. The asymmetric unit was found to contain
Figure 6.Binding of peptide 1 (green sticks) to 14-3-3ζ (white cartoon). Residues from 14-3-3 important for interaction with 1 are shown as sticks. Polar
interactions are depicted as black dotted lines, and hydrophobic contact surfaces from 14-3-3 are displayed as semitransparent spheres (PDB ID:
1A38).112
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three heterotetrameric complexes.56 Both intrinsically disor-
dered pHSPB6 N-terminal domains interact with the 14-3-3
dimer grooves identical to the cocrystal structure with the
phosphopeptides. Remarkably, the ACD dimer of HSPB6 was
found to dock onto one 14-3-3 unit, resulting in an asymmetric
overall complex (Figure 5), which is in contrast to the structures
described above. The interaction surface spans ∼400 Å2 and
contains an essential salt bridge between Arg224 (14-3-3) and
Glu86 (HSPB6). The positioning of the ﬂexible parts of the
NTDs not covered in the electron density were further
characterized in solution by small-angle X-ray scattering,
conﬁrming the 2:2 stoichiometry of the complex. The authors
state that by fully sequestering 14-3-3 binding sites, the
chaperone HSPB6 blocks interactions with other partner
proteins, thus acting as a phospho-switching 14-3-3 regulator.
■ INHIBITORS OF 14-3-3 PPIS
R18 Peptide.The ﬁrst reported 14-3-3 PPI inhibitor, peptide
R18 (1) (20 amino acid residues), was identiﬁed from a phage
display by the Fu Laboratory.111 In the 14-3-3 complex crystal
structure, the central sequence (WLDLE) can be seen in the
amphipathic binding groove of 14-3-3.112 This structure revealed
that, in addition to salt-bridge interactions between the carboxyl
group of the glutamic acid side chain and three arginines of 14-3-
3, there is an extensive hydrophobic contact surface between the
two leucine residues of 1 and a number of 14-3-3 residues (Figure
6). In this way, 1 eﬃciently exploits the amphipathic character of
the 14-3-3 binding channel to compete for both phosphor-
ylation-dependent and -independent 14-3-3 PPIs. In later
studies, Fu et al. showed that expression of a longer peptide of
64 amino acid residues with two such inhibiting sequences
resulted in apoptosis, sensitized cancer cells for the antineoplastic
drug cisplatin, and suppressed tumor growth in mice.113,114
These breakthrough studies with 1 proved the principal
feasibility and eﬃcacy of inhibiting 14-3-3 PPIs.
ExoS Macrocyclic Peptide. The groups of Ottmann and
Grossmann recently developed a strategy for the macro-
cyclization of bioactive peptides with an irregular secondary
structure and showed that macrocyclic molecules derived from
peptides containing 14-3-3 binding motifs can eﬃciently inhibit
the interaction between 14-3-3ζ and their binding partners.115 As
a proof of concept, they prepared macrocyclic peptides targeting
the interaction between 14-3-3ζ and the virulence factor of the
pathogenic bacterium Pseudomonas aeruginosa Exoenzyme S
(ExoS). These inhibitors were prepared from the ExoS peptide
stretch that binds to 14-3-3 in an irregular and mostly extended
conformation (Figure 7A, sequence Q420GLLDALDLAS430) by
replacing two hydrophobic residues crucially involved in 14-3-3
binding with non-natural amino acid residues cross-linked by a
(CH2)n chain. The most eﬃcient inhibition was obtained for the
βSS12 (2) inhibitor in which residues Leu422 and Ala425 were
replaced with S-conﬁgured non-natural amino acid residues
cross-linked with the chain containing 12 methylene groups
(Figure 7B and C).115 This macrocyclic inhibitor binds to 14-3-
3ζ with ∼30-fold higher aﬃnity compared to that of the
unmodiﬁed peptide (a Kd value of 41 nM vs 1.14 μM). The
structural analysis revealed that the hydrophobic cross-link is
involved in interactions with nonpolar residues within the ligand
binding groove of 14-3-3ζ, whereas the conformation of the
backbone is very similar to that of the unmodiﬁed peptide.
Further biophysical analyses suggested that the improved
binding aﬃnity resulting from the incorporation of the cross-
link comes from the signiﬁcantly decreased conformational
ﬂexibility of the macrocyclic molecule. Because all 14-3-3 binding
Figure 7. Structural characterization of the 14-3-3ζ/Exo S interface. (A) Wild-type ExoS (orange sticks) bound to 14-3-3ζ (white and blue surface).
ExoS establishes an extensive hydrophobic contact interface with 14-3-3 with its four leucine residues (Leu422, Leu423, Leu426, Leu428) binding to a
hydrophobic patch (blue surface) in the 14-3-3 channel (PDB ID: 2O02).67 (B) Structural superimposition of wild-type ExoS (orange cartoon and
sticks) and the 12-carbon-linker cyclic peptide 2 (green cartoon and sticks) derived from ExoS (PDB ID: 4N84).115 (C) The 12-carbon linker of 2
engages a semicircular, hydrophobic ring in 14-3-3 (white, semitransparent surface and blue sticks; PDB ID: 4N84).115 (D) Further optimization of the
constrained peptide derived from ExoS using an alkyne-cross-link in 3 (PDB ID: 5J31).116
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motifs structurally characterized so far adopt irregular and
extended conformations within the 14-3-3 ligand-binding
grooves, this approach should be applicable to the majority of
14-3-3 binding interactions. Figure 7D shows the crystal
structure of an ExoS-derived peptide H (3), which has been
obtained by a ring-closing alkyne metathesis used here for the
ﬁrst time for the stabilization of an irregular peptide secondary
structure.116
Tau Epitope. On a cellular level, the most striking
pathological hallmark of Alzheimer’s disease (AD) is the
occurrence of protein deposits like neuroﬁbrillary tangles
(NFTs) and amyloid plaques. NFTs are composed of hyper-
phosphorylated Tau displaying paired helical ﬁlaments. NFTs
have been found to contain substantial amounts of 14-3-3
proteins, implicating them in the pathophysiology of AD.117
Furthermore, 14-3-3 proteins have been found to directly bind to
Tau in solution via the phosphorylated residues Ser214 and
Ser324 as important determinants of binding.118,119 Previously,
we solved the crystal structure of 14-3-3 in complex with
synthetic peptides comprising the phosphorylation sites pSer214
and pSer324.120 The sequence surrounding pSer214
(211RTPpSLPTP218) is especially interesting with three proline
residues as notable structural features (Figure 8A). In particular,
Pro218 occupies a position that is not used by most of the other
structurally elucidated 14-3-3 recognition motifs. This observa-
tion inspired the rational design of peptide-based inhibitors using
this position (Pro218) in the Tau peptide for chemical
modiﬁcations that would result in peptides displaying increased
aﬃnity to 14-3-3.
This concept was recently demonstrated by the groups of
Ottmann, Milroy, and Landrieu who designed a potent inhibitor
of the 14-3-3/Tau interaction as guided by cocrystal structures of
the protein−stabilizer and protein−inhibitor complexes.121 The
superposition of cocrystal structures of 14-3-3 complexes with
Fusicoccin A (stabilizer) and Tau epitope (inhibitor, sequence
RTPpSLPTP) showed that the C-terminal Pro218 residue of the
Tau epitope and the A ring of Fusicoccin A overlap. This
suggested that the poor binding aﬃnity of this phosphopeptide
for 14-3-3 could be improved by extending its C-terminus with a
hydrophobic group to target the highly conserved hydrophobic
pocket within the amphiphilic groove of 14-3-3, which led to 14-
3-3 inhibiting modiﬁed peptides 109B (4), 126B (5), and 201D
(6) (Figure 8B−D).121 Indeed, the chimeric inhibitor containing
the sterically bulky and conformationally rigid benzhydryl
pyrrolidine moiety at the C-terminus of the Tau epitope
bound to 14-3-3 with 3 orders of magnitude higher binding
aﬃnity compared to that of the unmodiﬁed phosphopeptide.
Consequent NMR spectroscopic studies on 14-3-3ζ and full-
length Tau conﬁrmed that this chimeric compound inhibits the
binding of 14-3-3ζ to phosphorylated full-length Tau by
disrupting its interaction with the phospho-epitope sites located
within the C-terminal part of Tau.
2-5, Prodrug 15, and 19a. Shao et al. reported in 2010 a 14-
3-3 PPI inhibitor called 2-5 (7) that was found using the small-
molecule microarray (SMM) technique.122 The library was based
on an optimal 14-3-3 binding amino acid sequence
(RFRpSYPP), where they coupled 50 diverse amines to the C-
terminus of the N-terminal peptide (RFRpS) or 243 diverse acid
Figure 8.Targeting the 14-3-3σ/TaupS214 interface with modiﬁed peptides. (A)Wild-type TaupS214 (golden sticks) bound to 14-3-3σ (white surface
and white sticks). Residues from 14-3-3σ important for binding are shown as labeled sticks; polar contacts are depicted as black dotted lines (PDB ID:
4FL5).121 (B) Structural superimposition of wild-type TaupS214 (golden sticks) and the modiﬁed Tau-peptide 4 (green sticks, PDB ID: 4Y32) binding
to 14-3-3σ (white surface).121 (C) Structural superimposition of wild-type TaupS214 (golden sticks) and the modiﬁed Tau-peptide hybrid 5 (magenta
sticks, PDB ID: 4Y5I) binding to 14-3-3σ (white surface).121 (D) Structural superimposition of wild-type TaupS214 (golden sticks) and the modiﬁed
Tau-peptide hybrid 6 (purple sticks, PDB ID: 4Y5I) binding to 14-3-3σ (white surface).121
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building blocks to the N-terminus of the C-terminal peptide
(pSYSPP). These hybrids were spotted on a glass slide, and
binding of ﬂuorescently labeled GST-14-3-3 was measured. Five
hits were found with Kd values between 0.6 and 1.03 μM, of
which three featured a substitution of the N-terminal peptide
part and two of the C-terminal peptide part. By combining these
fragments into the six possible nonpeptidic molecules,
compounds were found with IC50 values between 2.6 and 3.6
μM (ﬂuorescence polarization (FP) assay), including 7 (Figure
9A).
Phospho-serine mimetic prodrug 15 (8) based on 7 was
reported that showed potent 14-3-3 inhibitory activity in cells.123
The basic idea of the group of Borch was to transform bioactive
peptides with phospho-serine groups, which suﬀer from poor
membrane permeability and hydrolysis by phosphatases, into
stable and cell permeable molecules with druglike properties.
The phosphate to serine bridging oxygen group of 7was replaced
by a diﬂuoromethylene linker with the aim of preventing
phosphatase cleavage under physiological conditions. This also
enables the retention of an appropriate pKa to keep the
phosphate mimetic in a doubly charged state to maintain all
essential interactions. For enabling membrane permeability, the
two charges of the phosphonate group were temporarily
neutralized by derivatization of the two phosphonate oxygens
with nitro-furfuryl and 4-chloro-N-methylbutan-1-amine groups
(Figure 9B). Upon entry into the cell, the nitrofurfuryl group was
cleaved oﬀ by enzymatic reduction and spontaneous expulsion to
deliver a phosphoamidate anion. Subsequent intracellular
cyclization of an intermediate followed by spontaneous
hydrolysis yields the biologically active phosphonate product
19a (9).123 Compound 8 inhibits viability of DG75 leukemia
cells with an IC50 value of 5 μM and induces apoptosis in the
same concentration range, whereas free phosphonate 9 does not
show any signiﬁcant inhibition at concentrations up to 100 μM.
For conﬁrming the relevance of 14-3-3 proteins for the cellular
eﬀects of compound 8, a cellular assay for measuring 14-3-3-
mediated inhibition of FOXO transcription factors was used.
FOXO3A is a member of the Forkhead family of transcription
factors that is inactivated by Akt1 phosphorylation and
subsequent 14-3-3 binding. FOXO3a-dependent reporter gene
activation was abolished by cotransfection with Akt1 in DG75
cells. The repressed FOXO3a activity was recovered in a dose-
dependent manner by addition of compound 8 in concordance
with reduced retention of phosphorylated FOXO3a by 14-3-3 in
the cytoplasm. Active metabolite 9 was able to inhibit the
interaction between immobilized 14-3-3τ and phosphorylated
FOXO3a at physiologically relevant concentrations in lysates of
DG75 leukemia cells transfected with FOXO3a and Akt1,
whereas prodrug 8 was inactive.
BV01, BV02, BV101, and 9.The group of Botta reported the
identiﬁcation of small-molecule inhibitors of 14-3-3σ PPIs by
using structure-based pharmacophore modeling, virtual screen-
ing, and molecular docking simulations with library design and
organic synthesis. They started by in silico screening of 200,000
compounds from the ASINEX chemical collection, of which 14
compounds were eventually selected and tested in cellular and
biochemical assays. This resulted in the identiﬁcation of BV02
(12) as a lead inhibitor of the interaction between 14-3-3σ and
cAbl in chronic myelogenous leukemia (CML) (Figure 9C).124
Indeed, 12 was able to inhibit 14-3-3/c-Abl interaction and
Figure 9. (A) Chemical structure of compound 7.122 (B)Membrane permeable prodrug 8 is converted to active component 9 by intracellular metabolic
transformation.123 (C) Chemical structure of 14-3-3 PPI inhibitors 10−13 identiﬁed by the group of Botta. The reversible hydration pathway converts
12 to 13 and vice versa.124,126,127
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promote c-Abl nuclear translocation at low micromolar
concentration in Ba/F3 cells expressing the wild-type Bcr-Abl
as well as its Imatinib-resistant T315I mutation.125 Accordingly,
12 represented a useful starting point for the development of an
alternative treatment of CML, particularly for the Imatinib-
resistant forms.
Following the discovery of 12, two additional 14-3-3 PPI
inhibitors have been reported. These molecules, namely BV01
(10) and BV101 (11) (Figure 9C), were also initially discovered
by an in silico approach,126 and promoted c-Abl nuclear
translocation in Ba/F3 cells expressing the WT and the
Imatinib-resistant T315I-mutated Bcr-Abl constructs. Further-
more, the interaction of 10 with 14-3-3σ was supported by
transfer NOE experiments.126 In 2014, the same group published
the discovery of compound 9 (13, Figure 9C), a phthalimide
derivative of 12 that is able to promote c-Abl nuclear
translocation as well as to sensitize multidrug-resistant (MDR)
cancer stem cells.127 This discovery was facilitated by in silico
docking of a virtual library of 12 and 10 analogues to a 14-3-3σ
crystal structure using a well-established computational proto-
col.124 The most promising molecules were synthesized and
submitted to biological tests. Most notably, molecule 13 was
found to promote c-Abl nuclear translocation at 25 μM and has
been shown to decrease the IC50 of doxorubicin by increasing its
accumulation in MDR cancer cells at 10 μM concentration.
Subsequently, it was discovered that 13 was the product of
spontaneous dehydration of 12 under aqueous conditions
(Figure 9C) and was, in fact, the bioactive form of 12, as
shown by a detailed NMR spectroscopy study.128 The direct
interaction between 13 and recombinant 14-3-3σ was demon-
strated by NOESY experiments, thus corroborating the
mechanism of action of 13 at the molecular level. Indeed, in
the presence of 14-3-3σ, the conversion of 13 back into 12 was
slowed down, indicating that temperature and pH are not the
only variables that inﬂuence the compounds interconversion.
This observation provides important information for the
appropriate setup of biological and biochemical experiments.
HSP20 Compound 85070. The phosphorylated form of
HSP20 (phospho-HSP20) interacts with 14-3-3 proteins, the
complex playing a regulating role on the actin depolymerizing
protein coﬁlin. Phospho-HSP20 competition with phospho-
coﬁlin for binding to 14-3-3 proteins frees phospho-coﬁlin,
resulting in its dephosphorylation and subsequent depolymeriza-
tion of the actin cytoskeleton. Free phosho-HSP20 is additionally
able to directly destabilize the cytoskeleton. The phospho-
HSP20/14-3-3 interaction could be a critical step in coﬁlin-
mediated disruption of actin stress ﬁbers and hence smooth
muscle relaxation. Small molecules targeting the phospho-
HSP20/14-3-3 interaction could thus lead to new therapeutic
compounds to treat constriction of the airways in asthma. By
screening a 58,019-compound library obtained from ChemDiv
and ChemBridge (SanDiego CA) by high-throughput polar-
ization assay, researchers at Prolexys Pharmaceuticals and the
Johns Hopkins Bloomberg School of Public Health identiﬁed
268 modulators.129 These primary screen hits show at least 20%
reduction of the polarization emission in the assay that was set up
Figure 10. (A) The proposedmechanism of adduct formation between 15 and 14-3-3ζ and the chemical structure of various derivatives of 15 (15A−C).
(B) Complex structure of covalent adduct formed between 15 and 14-3-3ζ upon X-ray irradiation (PDB ID: 3RDH).130
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using a FAM-labeled 8-mer phosphopeptide derived from
HSP20 to test for full-length 14-3-3 γ isoform (247 amino acid
residues) binding. Compounds belonging to the scaﬀold
PRLX24905 (US patent 20090136561) were further analyzed
by FP for their concentration-dependent activity of inhibition.
Structurally related scaﬀolds show a range of activity from no
inhibition to 50 μM IC50 for compound 85070 (14, structure not
disclosed).129 These compounds were additionally evaluated in
cell-based assays. Compound 14 was the most eﬃcient in
causing, in a dose-dependent manner, a decrease in cell stiﬀness,
decrease in contractile force in ASM cells, and an attenuation of
active force development of intact tissue ex vivo. For the time
being, the mechanism of action of compound 14 and the basis of
these functional eﬀects are not known.
FOBISIN101. In 2011, the group of Fu reported the ﬁrst
covalent 14-3-3 inhibitor FOBISIN101 (15, FOurteen-three-
three BInding Small molecule INhibitor).130 Compound 15
(Figure 10A), initially reported in 1998 as the P2X receptor
antagonist MRS-2159,131 was identiﬁed by screening of the
Sigma-Aldrich LOPAC library in a FP-based binding assay based
on 14-3-3γ and a phosphorylated Raf-1 peptide. Aﬃnity
chromatography was used to demonstrate the ability of 15 to
inhibit the binding of 14-3-3γ to two known 14-3-3γ binding
partners, Raf-1 and p-PRAS40, from COS-7 cell lysates.
Compound 15 was shown to be a pan-14-3-3 inhibitor and
inhibited the binding of PRAS40 to 14-3-3ζ and 14-3-3γ with
similar potencies (9.3 and 16.4 μM, respectively). Compound 15
also inhibited the 14-3-3-dependent activation of nonphosphory-
lated 14-3-3 client protein ExoS in a functional assay, suggesting
that 15 inhibits the binding of both phosphorylated and
nonphosphorylated client proteins. A limited SAR study of
analogues of 15was carried out, employing an ELISA assay based
on 14-3-3ζ and Raf-1. Compounds 15A and 15B (Figure 10A)
both exhibited almost complete loss of potency, indicating that
the phosphate and phenyldiazene moieties were required for
binding to 14-3-3ζ.
A structure of the complex of 15 and 14-3-3ζ was obtained by
X-ray crystallography, indicating the formation of an unexpected
covalent adduct with the protein (Figure 10B). This was
explained by X-ray-induced cleavage of the NN bond and
reaction of the radical thus formed with the side-chain terminal
nitrogen atom of Lys120. The phosphate moiety of 15 was
shown to interact with Lys49 (a key residue for recognition of
phosphorylated client proteins) and Asn173.
A color change (from orange to colorless) of the crystals upon
X-ray exposure was attributed to the loss of the conjugated
aromatic system caused by reductive photo cleavage of theNN
bond. MALDI-MS also showed that X-ray exposure was required
for formation of this covalent adduct as only irradiated samples
exhibited the 183 Da increase in molecular weight corresponding
to the 15 fragment observed in the crystal structure. However, X-
ray activation is not required for 15 to bind to 14-3-3ζ, as it was
able to inhibit binding of a Raf-1 peptide to 14-3-3ζ in an ELISA-
based assay. This suggests that the covalent bond may be a
radiation-induced crystallographic artifact rather than the
functional binding mode of 15 in the ELISA assay.
A similar pyridoxal phosphate derivative 15C (Figure 10A)
was reported by Ottmann and co-workers as a 14-3-3 protein-
binding ligand.132 In contrast to 15, no cleavage of the NN
bond was observed in the 1.8 Å resolution crystal structure of
15C complexed to 14-3-3σ. Instead, transimination with the
terminal side chain amino moiety of Lys122 (which corresponds
to 14-3-3ζ Lys120) led to a covalent adduct with the NN bond
and phenyldiazene moiety intact. The phosphate moiety of 15C
adopted a similar position to that observed for 15 bound to 14-3-
3ζ as reported by Fu. They then obtained a structure of 15 with
14-3-3σ, which in their hands also exhibited imine formation with
the aldehyde. It also exhibited with an intact diazene moiety;
however, the electron density indicated a high degree of ligand
ﬂexibility in this region when compared with the hydrazine
adduct observed by Fu et al. Ottmann and co-workers also
demonstrated attachment of up to four intact 15molecules to the
14-3-3σ protein using ESI-MS with no observed NN bond
cleavage. The diﬀerences in the observed mechanisms of
covalent complex formation of 15 were attributed to diﬀerences
in X-ray wavelength and MS conditions used.133 Further work is
needed to fully elucidate the exact mechanism of the diazene
cleavage and subsequent covalent adduct formation observed for
15.
UTKO1. In 2005, the group of Imoto reported the discovery of
the Aspergillus-derived natural product Moverastin as inhibitors
of cancer cell migration by the screening of microbial extracts.134
Natural Moverastin is produced as a diastereomeric mixture of
secondary alcohols, and separation led to the isolation of the pure
diastereoisomers Moverastin A (16A) and B (16B) (Figure
11).134 The Moverastins are members of the cylindrol family of
natural products, which are known inhibitors of farnesyl
transferase (FT).135 Structurally, the Moverastins diﬀer from
other cylindrols in that they possess a methylidene moiety rather
than a trisubstituted alkene.
HRas is a common human oncogene, and HRAS protein plays
a key role in cancer cell migration. HRAS activity is dependent on
posttranslational prenylation (farnesylation) by FT, which leads
to activation of HRAS by membrane localization. Inhibition of
FT therefore leads to a reduction of HRAS farnesylation and
inhibition of membrane localization, subsequently leading to a
reduction in cell migration and tumor metastasis. Compounds
16A and 16B were shown to inhibit FT in vitro with similar
potency and also shown to decrease the nuclear localization of
Ras in a tumor cell line.134
In 2011, the same group published a series of Moverastin
derivatives with enhanced inhibitory activity against the
migration of human oesophogeal tumor cells.136 The most
potent compound identiﬁed, rac-UTKO1 (17, Figure 11) had
Figure 11. Structures of 16A, 16B, 17, and biotinylated probe molecule
18.134,136,137
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3.5-fold increased potency on inhibition of cell migration (IC50
1.98 μM) compared to 16; however, 17 was shown not to inhibit
FT (IC50 > 100 μM), and therefore, another target was likely
responsible for its activity.136 Biotinylated UTKO1 derivative B-
UTKO1ox (18, Figure 11) was used as a probe in a series of
experiments to identify themolecular mode of action of 17.134,137
Coprecipitation experiments with 18 and unlabeled 17 identiﬁed
two 14-3-3 isoforms (ε and ζ) as potential 17-binding proteins of
which 14-3-3ζ was considered to be the most likely candidate for
the biological activity due to previous reports of its involvement
in cell migration. The direct binding of 17 to 14-3-3ζ was
conﬁrmed by a competition pulldown experiment using a GST-
tagged 14-3-3ζ protein. All seven mammalian 14-3-3 isoforms
were then tested for binding to 17, and 14-3-3ζ was conﬁrmed as
the isoform with the strongest binding aﬃnity. Compound 17
was also shown to bind to the C-terminal domain of 14-3-3ζ.
This C-terminal domain is the most variable region within the
14-3-3 family, and this was proposed as an explanation for the
selective binding of 17 to 14-3-3ζ. siRNA silencing of 14-3-3ζ led
to suppression of lamellopodia formation (which is key to cell
migration) in a tumor cell line thus increasing conﬁdence that the
observed eﬀect of 17 is due to binding to 14-3-3ζ.
Additional pulldown experiments with GST-tagged 14-3-3ζ
were performed to identify the relevant 14-3-3ζ partner proteins
with two proteins (Tiam1 and βPix) being identiﬁed as
promising candidates.134 siRNA knockdown experiments
showed only Tiam1 to have an eﬀect on cell migration and
inhibition of the binding of Tiam1 to 14-3-3ζ by 17 was
conﬁrmed both in cell lysates and cultured cells. Interestingly,
neither the stability nor cellular localization of Tiam1 was
aﬀected by 17, suggesting that a conformational change upon
binding to 14-3-3ζ is required for activation of Tiam1 and that
this is inhibited by 17.
Phosphonate-type Inhibitors of 14-3-3. Starting from the
identiﬁed RFRpSYPP binding motif of an inhibitory peptide of
14-3-3, Wu et al. derived cell-permeable small molecule PPI
inhibitor 7 that contains the phosphorylated central serine.122
The group of Ottmann went a step further and identiﬁed a small
molecule 14-3-3 inhibitor by means of virtual screening.138 An
implemented set of ﬁlters on a ZINC library of more than 8
million small molecules yielded 512 diverse compounds that
incorporate one phosphate or phosphonate group and obey the
Lipinski’s rule of ﬁve. Their virtual docking into a high-resolution
crystal structure of 14-3-3σ (PDB ID: 3P1N) and follow-up
analysis led to the synthesis and cocrystallization of 11 14-3-3
inhibitors (e.g., compound B2 (19, Figure 12)).138 A detailed
computational analysis of the binding mode of eight of these
molecules was performed by the group of Wang et al.139 They
showed that the hydrophilic residues (Arg56, Arg129, and
Tyr130 of 14-3-3σ) at the bottom of the binding pocket form
seven stable hydrogen bonds with the phosphate group. In
addition, two residues (Leu174 and Val178) in contact with a
moiety accommodating the phosphate group contribute large
van der Waals energies, and residue Leu126 provides large
electrostatic energies. This is in agreement with the statement
that the phosphate has the strongest pharmacophoric properties.
There are three unfavorable interactions with residues (Asp126,
Glu133, and Glu182) for inhibitor binding to protein. The
averaged free energies for these three residues in the eight
compounds are 0.93, 1.03, and 0.97 kcal/mol. Because the
aspartic acid and glutamic acid residues have negative charges,
they repel the phosphate group and attract the residues with
positive charge in the binding pocket. By contrast, several
residues surround the second hydrophobic moiety of the
inhibitors, whereas there are only weak interactions between
this part of the inhibitor and protein residues.
Molecular Tweezers. Bier et al. published in 2013 another
class of phosphate-containing inhibitors called molecular
tweezers (Figure 13A and B).140 With crystal structures, they
showed that this molecule binds around residue Lys214 that is
positioned at the edge of the amphipathic binding groove of 14-
3-3σ (Figure 13C−E). By binding to this position, it can interfere
with the function of 14-3-3 as an adapter protein, inhibiting, for
example, the binding of phosphorylated C-Raf and unphos-
phorylated ExoS (Figure 13) to 14-3-3σ. Surprisingly, the crystal
structure of 14-3-3 in complex with the molecular tweezer
CLR01 (20) revealed only one molecule binding to 14-3-3σ.140
This was unexpected because 14-3-3σ displays 17 surface-
exposed lysine residues potentially able to bind this supra-
molecular ligand. Closer inspection of the environment of
Lys214 and extensive modeling of the 14-3-3σ/20 interaction
identiﬁed a set of structural requirements for the eﬃcient
interaction of the tweezer with lysine residues. In particular, the
arrangement of a predominantly hydrophobic interaction surface
formed by Tyr213, Thr217, and Leu218 seems to be beneﬁcial
for a more stable accommodation of the tweezer molecule. These
structural ﬁndings can help in the design of more speciﬁc
molecular tweezers, an approach currently followed in the groups
of Schrader and Ottmann.
■ STABILIZERS OF 14-3-3 PPIS
Fusicoccanes. Fusicoccin A (21) is a diterpene glycoside
produced by the phytopathogenic fungus Phomopsis amygdali
(formerly Fusicoccum amygdali) that was initially described in the
mid-1960s to be a wilt-inducing toxin.141 It was, however, not
until 1994 that the molecular target was identiﬁed as the binary
complex between the regulatory domain of the plasma
membrane H+-ATPase (PMA) and 14-3-3 adapter proteins,
which 21 stabilizes by acting like a “molecular glue”.142 Since
then, 21 and the related natural product cotylenin A (22)145 and
semisynthetic (e.g., Fusicoccin THF (23),150 ISIR-005 (24)151)
fusicoccane analogues have proven to be valuable tool
Figure 12. Binding of phosphonate inhibitor 19 (cyan sticks) to 14-3-3σ
(white cartoon, sticks and surface). Residues from 14-3-3σ important for
accommodation of 19 are shown as sticks; polar interactions are
depicted as dotted black lines, and the semitransparent surface
represents hydrophobic contacts (PDB ID: 4DHT).138
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compounds to study the “molecular glue” model for stabilizing
14-3-3 binary structures (Figure 14).
Compound 21 itself has now been shown to stabilize 14-3-3
complexation with a number of medicinally relevant partner
proteins in humans. For example, 21 promotes platelet adhesion
to von Willebrand factor by stabilizing the 14-3-3 interaction
with the C-terminus of the human protein glycoprotein
(GP)Ibα.143 Compound 21 also stabilizes the 14-3-3 interaction
with the C-terminus of the F-domain of estrogen receptor α
(ERα) and thus inhibits ERα-dependent transcription.144
However, 21 stabilization is not limited to 14-3-3 partners
bearing C-terminal (or “mode III”) 14-3-3 binding motifs.
Although the physiological potency is relatively weak, 21 has
recently been shown to stabilize the 14-3-3 interaction with the
cystic ﬁbrosis transmembrane conductance regulator (CFTR),
thus promoting traﬃcking of CFTR to the plasma membrane.55
Compound 22 is another natural product produced by a
fungus (Cladosporium sp. 501-7W) that acts as a bioactive
Figure 13. Chemical structure of molecular tweezer 20 (A) and a 3D view of the molecule conformation it adopts for protein recognition (B). (C)
Binding of molecular tweezer 20 (yellow sticks) to Lys214 of 14-3-3σ (white sticks) and the electron density (blue mesh, 2FO-FC, contoured at 1.0 σ).
(D) Superimposition of the binding of molecular tweezer 20 (yellow spheres) and the ExoS peptide (416−430, purple sticks) to 14-3-3σ (white
surface). (E) Molecular tweezer 20 (yellow sticks and surface) binding to Lys214 of 14-3-3σ (white cartoon and sticks) (PDB IDs: 4HQW and
4HRU).140
Figure 14. Fusicoccane analogues, natural (21, and 22) or semi-synthetic (23, 24, and 25) that act as “molecular glue”model for stabilizing 14-3-3 binary
structures.142,145,150−152
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substance against plants.145 Years after its discovery as a
cytokinin-like substance, this natural product was reported to
induce diﬀerentiation in human acute myeloid leukemia in both
cell culture and mouse models.146,147 Interestingly, anticancer
properties were found by combining 22with other agents such as
vincristine.148 The crystal structure of 22 bound to a complex of
14-3-3 with the N-terminal binding motifs of the protein kinase
C-Raf published in 2013 gave important structural insight into
how 22 can mediate its antitumor activity.149
The 5-8-5-fused ring system of the fusicoccane scaﬀold is
highly complex, and thus, investigating structural variation in the
search for selectivity or enhanced potency is challenging.
Nevertheless, structure-based design and semisynthesis have
enabled the discovery of potent analogues. For example,
semisynthetic derivative 23 (Figure 15A−C) was designed as a
“mode III”-speciﬁc stabilizer and resulted in a 20-fold
stabilization of the interaction between 14-3-3 and the potassium
channel TASK3.150 In this study, a number of other fusicoccanes
Figure 15. Semisynthetic derivatives 23, 26, and 27 stabilize the interaction between 14-3-3σ and TASK3 peptide. (A) Semisynthetic derivative 23
(purple sticks) and the C-terminus of TASK3 peptide (yellow sticks) in the binding groove of 14-3-3σ (cyan surface). (B) Electron density (red, blue,
and black mesh, 2FO-FC, contoured at 1.0 σ) around 23 (purple sticks), C-terminus of TASK3 peptide (yellow sticks), and 14-3-3σ (green sticks). (C)
Comparison of 23 (purple sticks) with 26 (orange sticks) and 27 (yellow sticks) in the binding pocket formed by 14-3-3σ (cyan surface) and TASK3
peptide (yellow surface) (PDB IDs: 3SMN, 3SMM, and 3SP5).150
Figure 16. Comparison among 27, 26, and 23 in the stabilization of a “mode III” binder (TASK3) and “mode I/II” binder (C-Raf). (A) Overlay of 27
(green sticks), 26 (orange sticks), and 23 (purple stick) in the 14-3-3σ/TASK3 peptide (yellow sticks) complex. (B) The C-ring of 27 does not clash
with “mode I/II” C-Raf peptide. (C) The hydroxylation of C12 in 26 clashes with the carbonyl oxygen of C-Raf P260. (D) The additional ring D of 23
clashes with both the carbonyl oxygen and the side group of C-Raf P260 (PDB IDs: 3SP5, 3SMM, 3SMN, and 4IEA).149,150
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like Fusicoccin J aglycone (26)150 and cotylenol (27)150 (the
aglycone of cotylenin) were tested (Figure 15C). The respective
crystal structures of the complexes of the diﬀerent fusicoccanes
with 14-3-3 and the TASK3 peptide revealed the structural basis
for their “mode III” preference (26, 22) or “mode III” speciﬁcity
(23, Figure 16A). With a C12-dehydroxy fusicoccane like 22,
concomitant binding of a “mode I” or “mode II” 14-3-3 partner
like C-Raf and consequently its stabilization is possible (Figure
16B). However, hydroxylation of C12, which is present in 21 and
26, introduces a steric conﬂict with the proline carbonyl oxygen
at position +2 C-terminal in the 14-3-3 binding motif of C-Raf
(Figure 16C). Whereas this steric conﬂict might not exclude
every “mode I” or “mode II” interaction with 14-3-3, the
additional ring system in 23makes this molecule a speciﬁc “mode
III” stabilizer whose binding to a 14-3-3/partner protein interface
should be signiﬁcantly hampered with any 14-3-3 interaction
motif that extends beyond the +1 position (Figure 16D).
Importantly, the utility of 23 could be demonstrated in Xenopus
oocytes, which have been transfected to express human TASK3.
Here, adding 10 μM 23 to the culturing solution results in a 45%
increase of TASK3 expression in the plasma membrane.150
More recently, C-12 dehydroxy derivative 24 (Figure 14) was
shown to be an analogue well-suited for the stabilization of 14-3-
3 interactions with partner proteins bearing internal (or “mode I
or II”) binding motifs.151 Biophysical and cellular experiments
showed 24 to stabilize the 14-3-3 − Gab2 PPI by a factor of 5.3
and the crystal structure of the ternary complex provided further
structural insight.151
The potential of fusicoccane semisynthetics is not limited to
the search for potent stabilizers. Ohkanda, Kato, and co-workers
elegantly demonstrated the power of intracellular oxime ligation
to generate a fusicoccane−peptide hybrid (25) that induced cell
death, presumably through inhibition of 14-3-3 PPIs (Figure
14).152 Interestingly, 25 that does not contain a phosphorylated
residue was shown to bind 14-3-3 with a Kd value of 0.37 μM,
stronger even than the interaction with a PMA2-derived
phosphopeptide (Kd = 1.24 μM).
152 This example not only
further highlights the potential for modiﬁed peptide inhibitors of
14-3-3 PPIs (i.e., based on ExoS and Tau as discussed above) but
also the importance of expanding the fusicoccane toolbox.
Perhaps the emergence of new synthetic approaches to
sesterterpenes153 can be coupled with previous total synthesis
eﬀorts154 to achieve this aim. Or perhaps ever greater
Figure 17.Compound 29 and derivative 30 stabilize the interaction between 14-3-3 and PMA2. (A) Chemical structures of 28−30. (B) Compound 29
(yellow spheres) in the binding groove of T14-3-3e (green surface) having contact with PMA2 CT30 (blue surface). (C) Close-up of the T14-3e/
PMA2/29 (green surface/blue surface/yellow sticks) interaction showing the electron density of 29 (gray mesh, 2FO-FC, contoured at 1.0 σ; PDB ID:
3M51).156,157
Figure 18. Crystal structure of the 14-3-3β/ChREBP/31 (AMP) complex. (A) Overview of ChREBP (purple cartoon) and 31 (yellow sticks and
semitransparent spheres) bound to a monomer of 14-3-3β (solid white surface). (B) Detailed view of the contacts between 31 (yellow sticks), ChREBP
(purple cartoon and sticks), and 14-3-3β (white cartoon and sticks). Polar contacts are depicted as black dotted lines (PDB ID: 5F74).158
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understanding of the structure and function of fusicoccadiene
synthase155 will provide the necessary starting points for diverse
synthetic strategies.
Epibestatin, Pyrrolidone1, and Pyrazole34. In 2010, the
results of the ﬁrst high-throughput screening for 14-3-3 PPI
stabilizers were published.156 Out of a library of 37,000 small
molecules, two compounds were found by a surface-based format
monitoring the binding of GFP-14-3-3 to surface-immobilized
PMA2-CT52: Epibestatin (28)156 and Pyrrolidone1 (29)156
(Figure 17). The crystal structures of these two compounds in
the 14-3-3/PMA2 complexes revealed two distinctive binding
pockets in the 14-3-3/PMA2 protein−protein interface. Two
years later, Pyrazole34 (30) was published.157 This was based on
optimization of the template of 29 in which the pyrrolidone
scaﬀold had been converted into a more rigid pyrazole ring.157
AMP/ChREBP. In 2016, the group of Uyeda published the
PPI-stabilizing eﬀect of AMP (adenosine monophosphate,
Figure 18A) (31) toward the complex of 14-3-3 and the
carbohydrate-response element-binding protein (ChREBP).158
ChREBP is a glucose-responsive transcription factor that is
implicated in the regulation of fat storage in the liver by
facilitating the conversion of carbohydrate to fat.159,160 The N-
terminal region of ChREBP binds to 14-3-3 proteins and
importin, which regulates subcellular localization in response to
changing glucose levels. Low glucose leads to phosphorylation of
Ser196 of ChREBP by PKA followed by complexation with 14-3-
3 and cytoplasmic sequestration.161 In addition to the
phosphorylation-dependent regulation of the 14-3-3/ChREBP
interaction, a number of metabolites have been shown to
inﬂuence this PPI, among them β-hydroxybutyrate (β-HB) and
acetoacetate (AcAc). Both β-HB and AcAc have been shown to
stabilize 14-3-3 binding to ChREBP,162 a ﬁnding that was later
extended to 31 including a convincing structural biology
explanation for this activity.158 A very interesting feature of the
interaction between 14-3-3 and ChREBP is that it also employs a
phosphorylation-independent binding mechanism. Here, the α2
helix of ChREBP (residues 117−137) binds to the central
channel of 14-3-3β, engages both polar and hydrophobic
interactions, and is partly dependent on the presence of a sulfate
ion in the phosphate-accepting pocket of 14-3-3.163 Using the
same crystallization conditions but adding 100 mM 31 during
complexation of 14-3-3β and ChREBP yielded crystals showing
that 31 occupies the same place where, in the phosphorylation-
dependent 14-3-3 complexes, the phosphorylated serine or
threonine residues can be found (Figure 18B). The phosphate
group binds to Lys51, Arg58, Arg129, and Tyr130 residues,
which are also used to accommodate the phosphorylated motifs
of 14-3-3 partner proteins. In addition, the adenine ring of 31
interacts with Ser47 of 14-3-3, and maybe most importantly for
its PPI stabilizing activity, the phosphate establishes polar
contacts with Trp127 and Arg128 of ChREBP. Finally, Asn124 of
ChREBP forms a contact with one of the hydroxyl groups of
AMP’s sugar ring. Compound 31 is thus a direct orthosteric PPI
interface stabilizer (Figure 18C).
■ CONCLUSIONS AND FUTURE DIRECTIONS
In this perspective, we demonstrated that 14-3-3 proteins are
highly relevant targets in drug discovery and provide a valuable
tool in chemical biology. By presenting an overview of the wide
range of 14-3-3 PPI modulators currently published, we illustrate
the increasing evidence for the potential to modulate the activity
of key proteins in various physiological processes, including Tau,
p53, HSP20, and LRRK2, by targeting their distinct interaction
with 14-3-3. Importantly, in addition to structural insights on the
molecular mechanisms of the diﬀerent small molecules, in a
number of cases the inﬂuence on biological pathways has been
studied, resulting in promising ﬁndings in cell-based model
systems relevant to treating a variety of diseases (e.g., Alzheimer’s
disease, various cancers, asthma, and cystic ﬁbrosis). Bearing in
mind that the modulation of only a small percentage of the
several hundred identiﬁed 14-3-3 PPIs has been investigated so
far, we believe that this is just the start of the opportunity that 14-
3-3 PPI modulation can oﬀer. However, this wide range of
opportunities that 14-3-3 interaction partners hold also provides
focus to where the biggest obstacles in the ﬁeld will lie.
The great number of similar binding modes of 14-3-3 PPI
partners makes it diﬃcult for small molecule modulation to
achieve speciﬁcity for one partner over the others. This is most
strikingly illustrated by 14-3-3 PPI inhibitors, where binding of a
competing molecule in the 14-3-3 binding groove will cause
inhibition of binding of most other 14-3-3 binding partners,
potentially leading to many side eﬀects. For circumventing the
nonspeciﬁc targeting of the phospho-binding pocket of 14-3-3
proteins, two approaches can be envisioned for future eﬀorts
toward more selective 14-3-3 PPI modulation. First, although
based on a somewhat limited set of 14-3-3 crystal structures in
complex with larger domain partner proteins, it is becoming clear
that 14-3-3 itself is a relatively rigid molecule that allows for the
docking of ﬂexible partner proteins onto diﬀerent surfaces of its
dimer. By studying the “hot spots” responsible for the binding of
the two partner proteins in these binary structures, we observe
that there is a considerable variety of potentially distinct
druggable pockets. In this regard, we very recently found that
fragments from an NMR-based screen can bind to secondary
binding sites outside the central phosphopeptide-accepting
binding channel.164 The identiﬁed pockets are located on the
upper rim of the 14-3-3 dimer, which is less conserved than the
central channel and is used for binding of 14-3-3 to AANAT and
FT. Second, the general approach of stabilization of 14-3-3 PPIs
is suggested to be likely more beneﬁcial compared to inhibition.
This has already been illustrated by several examples where small
molecules have been identiﬁed that make contacts with both 14-
3-3 and the PPI partner. In this manner, they act as molecular
glue and thereby provide better opportunities for selectivity. The
semisynthesis of the Fusicoccane family provides a great case
study for selectivity in the 14-3-3 PPI stabilization; the
hydroxylation of C12 promotes a preference for stabilization
for C-terminal “mode III” binders over “mode I/II” binders.
Furthermore, molecules like 30 may be a good starting point to
obtain selectivity over other 14-3-3 PPI partners by expanding
the molecule and gaining more contact with the desired 14-3-3
binding partner. To reach the full potential in the ﬁeld of 14-3-3
PPI modulation, we need to think “out-of-the-binding groove”
and explore the rest of the protein. This should be possible by
using a combination of high-throughput screening, fragment-
based approaches, and rational design, and success will lead to
the realization of small molecule inhibition and stabilization of
14-3-3 PPIs as a viable option in drug discovery.
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